Please ensure Javascript is enabled for purposes of website accessibility

Despite Last-Minute Changes, Senate Bill Deals Big Blow to Renewable Energy

10 hours ago

Trump-Backed Tax-Cut and Spending Bill Passes US Senate

11 hours ago

Homeland Security Secretary Noem Says CNN May Be Prosecuted Over Report on Migration App

12 hours ago

Israeli Officials to Hold Ceasefire Talks in Washington Amid Military Escalation in Gaza

13 hours ago

Trump Escalates Feud With Musk, Threatens Tesla, SpaceX Support

13 hours ago

Musk Vows to Punish Lawmakers Who Back Trump’s Spending Bill

1 day ago

Will Valadao Spoil Trump’s Plan for July 4th ‘Big Beautiful Bill’ Signing?

1 day ago

Shaver Lake and Reedley 4th of July Shows Are Wednesday. Who Else Is Celebrating?

1 day ago
Merck Says Experimental Pill Cuts Worst Effects of COVID-19
gvw_ap_news
By Associated Press
Published 4 years ago on
October 1, 2021

Share

WASHINGTON — Drugmaker Merck said Friday that its experimental COVID-19 pill reduced hospitalizations and deaths by half in people recently infected with the coronavirus, potentially a leap forward in the global fight against the pandemic.

The company said it will soon ask health officials in the U.S. and around the world to authorize the pill’s use. A decision from the U.S. Food and Drug Administration could come within weeks after that, and the drug, if OK’d, could be distributed quickly soon afterward.

If cleared, it would be the first pill shown to treat COVID-19. All other therapies now authorized in the U.S. require an IV or injection. A pill taken at home, by contrast, would ease pressure on hospitals and could also help curb outbreaks in poorer and more remote corners of the world that don’t have access to the more expensive infusion therapies.

“This would allow us to treat many more people, much more quickly and, we trust, much less expensively,” said Dr. William Schaffner, an infectious disease expert at Vanderbilt University, who was not involved in the research.

Early Results Show Pill Cuts Symptoms and Deaths by Half

Merck and its partner Ridgeback Biotherapeutics said early results showed patients who received the drug, called molnupiravir, within five days of COVID-19 symptoms had about half the rate of hospitalization and death as patients who received a dummy pill. The study tracked 775 adults with mild-to-moderate COVID-19 who were considered higher risk for severe disease due to health problems such as obesity, diabetes or heart disease. The results have not been peer reviewed by outside experts, the usual procedure for vetting new medical research.

Among patients taking molnupiravir, 7.3% were either hospitalized or died at the end of 30 days, compared with 14.1% of those getting the dummy pill. There were no deaths in the drug group after that time period compared with eight deaths in the placebo group, according to Merck.

An independent group of medical experts monitoring the trial recommended stopping it early because the interim results were so strong. That is typical when early results show so clearly that a treatment works that there is no need for further testing before applying for authorization. Company executives said they plan to submit the data for review by the FDA in coming days.

Experts Stress the Importance of Vaccination First

Even with the news of a potentially effective new treatment for COVID-19, experts stressed the importance of vaccines for controlling the pandemic, given that they help prevent transmission and also reduce the severity of illness in those who do get infected.

“We love having more treatments available, but prevention is the first goal,” Schaffner said. “Vaccination continues to be the foundation of how we can get ahead of COVID.”

Still, effective therapies will be critical given that billions of people around the world remain unvaccinated.

“It exceeded what I thought the drug might be able to do in this clinical trial,” said Dr. Dean Li, vice president of Merck Research Laboratories. “When you see a 50% reduction in hospitalization or death that’s a substantial clinical impact.”

Merck only studied its drug in people who were not vaccinated. But FDA regulators may consider authorizing it for broader use in vaccinated patients who get COVID-19 symptoms.

Pill Interferes With Virus’ Ability to Reproduce Itself

Patients take eight pills per day for five days. Side effects were reported by both groups in the Merck trial, but they were slightly more common among the group that received a dummy pill. The company did not specify the problems.

Earlier study results showed the drug did not benefit patients who were already hospitalized with severe disease.

The U.S. has approved one antiviral drug, remdesivir, specifically for COVID-19, and allowed emergency use of three antibody therapies that help the immune system fight the virus. But all the drugs have to given by IV or injection at hospitals or medical clinics, and supplies have been stretched by the latest surge of the delta variant.

Health experts including the top U.S. infectious disease expert Dr. Anthony Fauci have long called for a convenient pill that patients could take when COVID-19 symptoms first appear, much the way the standard flu medication Tamiflu helps fight influenza. Such medications are seen as key to controlling future waves of infection and reducing the impact of the pandemic.

Merck’s pill works by interfering with the coronavirus’s ability to copy its genetic code and reproduce itself. It has shown similar activity against other viruses.

U.S. Government to Purchase Pills Pending FDA Approval

The U.S. government has committed to purchase 1.7 million doses of the drug if it is authorized by the FDA. Merck has said it can produce 10 million doses by the end of the year and has contracts with governments worldwide. The company has not announced prices.

Several other companies, including Pfizer and Roche, are studying similar drugs that could report results in the coming weeks and months.

Merck had planned to enroll more than 1,500 patients in its late-stage trial before the independent board stopped it early. The results reported Friday included patients enrolled across Latin America, Europe and Africa. Executives estimated about 10% of patients studied were from the U.S.

RELATED TOPICS:

DON'T MISS

What Are Fresno Real Estate Experts Predicting for 2025 and Beyond?

DON'T MISS

First California EV Mandates Hit Automakers This Year. Most Are Not Even Close

DON'T MISS

Trump Pulls Back 150 Guard Troops From Federal Duties in California

DON'T MISS

Trump Says Israel Has Agreed to Conditions to Finalize 60-Day Gaza Ceasefire

DON'T MISS

Fresno County Man Arrested for Suspected Arson Hours After Separate Wildfire

DON'T MISS

New California Environmental Rollbacks Could Boost Housing Projects in Fresno

DON'T MISS

Iran Made Preparations to Mine the Strait of Hormuz, US Sources Say

DON'T MISS

Fresno Unified’s Embattled Nikki Henry Exits. ‘I Own My Mistake. I Won’t Let It Own Me.’

DON'T MISS

Trump Floats Daughter-in-Law Lara Trump for Senate Run in North Carolina

DON'T MISS

Google Hit With $314 Million US Verdict in Cellular Data Class Action

DON'T MISS

Tulare County Wildfire Prompts Advisory in Three Rivers Area

DON'T MISS

O’Brien Launches Fresno County Schools Chief Campaign by Handing Out ‘Homework’

UP NEXT

US Supreme Court Preserves Key Element of Obamacare

UP NEXT

US Supreme Court Backs South Carolina Effort to Defund Planned Parenthood

UP NEXT

West Nile Virus Detected in Mosquitoes in Fresno County

UP NEXT

St. Agnes’ New Chief Medical Officer Is a Kidney Care Expert

UP NEXT

US Health Secretary Kennedy Says He Brought Back 722 CDC Employees, 220 at NIH

UP NEXT

Marijuana’s Links to Heart Attack and Stroke Are Becoming Clearer

UP NEXT

‘Little Lobbyists’ Urge Senators to Oppose Trump’s Bill Cutting Medicaid

UP NEXT

US FDA Approves Gilead’s Twice-Yearly Injection for HIV Prevention

UP NEXT

Wired Wednesday: Physician Alleges Improper Inmate Care at Fresno County Jail

UP NEXT

US to Drop Guidance to Limit Alcohol to One or Two Drinks per Day, Sources Say

New California Environmental Rollbacks Could Boost Housing Projects in Fresno

5 hours ago

Iran Made Preparations to Mine the Strait of Hormuz, US Sources Say

5 hours ago

Fresno Unified’s Embattled Nikki Henry Exits. ‘I Own My Mistake. I Won’t Let It Own Me.’

5 hours ago

Trump Floats Daughter-in-Law Lara Trump for Senate Run in North Carolina

5 hours ago

Google Hit With $314 Million US Verdict in Cellular Data Class Action

6 hours ago

Tulare County Wildfire Prompts Advisory in Three Rivers Area

6 hours ago

O’Brien Launches Fresno County Schools Chief Campaign by Handing Out ‘Homework’

6 hours ago

Trump Says US Could Reach Trade Deal With India, Casts Doubt on Deal With Japan

6 hours ago

Jury Reaches Verdict on Some Counts at Sean ‘Diddy’ Combs’ Sex Trafficking Trial

6 hours ago

How Wimbledon Is Tackling Its Hottest Opening on Record

7 hours ago

Trump Pulls Back 150 Guard Troops From Federal Duties in California

LOS ANGELES — The Trump administration released about 150 National Guard troops on Tuesday in the first pullback since it dispatched a milit...

3 hours ago

3 hours ago

Trump Pulls Back 150 Guard Troops From Federal Duties in California

An Israeli military convoy manoeuvres near the Israel-Gaza border, as seen from Israel, July 1, 2025. (Reuters/Amir Cohen)
4 hours ago

Trump Says Israel Has Agreed to Conditions to Finalize 60-Day Gaza Ceasefire

Abel Joel Garcia Zarate, 39, of Biola, was arrested Sunday, June, 30, 2025, in Madera County on suspicion of starting a wildfire just hours after crews responded to a separate blaze sparked by farm equipment. (Madera County SO)
4 hours ago

Fresno County Man Arrested for Suspected Arson Hours After Separate Wildfire

5 hours ago

New California Environmental Rollbacks Could Boost Housing Projects in Fresno

An aerial view of the Iranian shores and the island of Qeshm in the strait of Hormuz, December 10, 2023. REUTERSStringerFile Photo
5 hours ago

Iran Made Preparations to Mine the Strait of Hormuz, US Sources Say

5 hours ago

Fresno Unified’s Embattled Nikki Henry Exits. ‘I Own My Mistake. I Won’t Let It Own Me.’

Lara Trump looks on during Republican presidential nominee and former U.S. President Donald Trump's rally, at the Palm Beach County Convention Center in West Palm Beach, Florida, U.S., November 6, 2024. (Reuters File)
5 hours ago

Trump Floats Daughter-in-Law Lara Trump for Senate Run in North Carolina

A Google logo is seen at a company research facility in Mountain View, California, U.S., May 13, 2025. (Reuters File)
6 hours ago

Google Hit With $314 Million US Verdict in Cellular Data Class Action

Help continue the work that gets you the news that matters most.

Search

Send this to a friend